The Impasse on Overall Survival in Oncology Reimbursement Decision-Making: How Can We Resolve This?
Michael Patrick Lux, 1 Oriana Ciani, 2 William CN Dunlop, 3 Andrea Ferris, 4 Michael Friedlander 5 1Department of Gynecology and Obstetrics, Frauenklinik St. Louise Paderborn, St. Josefs-Krankenhaus Salzkotten, Frauen- und Kinderklinik St. Louise Paderborn, Paderborn, Germany; 2Centre for Research...
Guardado en:
Autores principales: | Lux MP, Ciani O, Dunlop WCN, Ferris A, Friedlander M |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/7141aa4bc7d84c90867649d7c0dedaf4 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Progression‐free survival assessed per immune‐related or conventional response criteria, which is the better surrogate endpoint for overall survival in trials of immune‐checkpoint inhibitors in lung cancer: A systematic review and meta‐analysis
por: Guang‐Li Zhu, et al.
Publicado: (2021) -
Progression-free survival/time to progression as a potential surrogate for overall survival in HR+, HER2– metastatic breast cancer
por: Forsythe A, et al.
Publicado: (2018) -
The influence of age on health valuations: the older olds prefer functional independence while the younger olds prefer less morbidity
por: Hofman CS, et al.
Publicado: (2015) -
Definitions and elements of endpoints in phase III randomized trials for the treatment of COVID-19: a cross-sectional analysis of trials registered in ClinicalTrials.gov
por: Kentaro Sakamaki, et al.
Publicado: (2021) -
Observations on the Changing Shape of the Ice Mass and the Determination of the Sublimation End Point in Freeze-Drying: An Application for Through-Vial Impedance Spectroscopy (TVIS)
por: Bhaskar Pandya, et al.
Publicado: (2021)